Tactile Systems Technology, Inc.

Tactile Systems Technology, Inc. Q3 2025 Earnings Recap

TCMD Q3 2025 November 4, 2025

Tactile Medical reported robust third-quarter results with total revenue of $85.8 million, achieving a 17% year-over-year increase, driven by significant growth in both lymphedema and airway clearance segments. The company raised its full-year revenue guidance amid strong operational progress and an expanded field sales team.

Earnings Per Share Beat
$0.36 vs $0.16 est.
+125.0% surprise
Revenue Miss
85755000 vs 93798400 est.
-8.6% surprise

Market Reaction

1-Day +40.65%
5-Day +57.64%
30-Day +63.03%

Key Takeaways

  • Total revenue grew 17% year-over-year to $85.8 million; lymphedema revenue up 11% and airway clearance revenue surged 71%.
  • Adjusted EBITDA rose 34% year-over-year to $14.4 million, reflecting improved profitability.
  • Strengthened field sales organization achieved record headcount of 329 reps, supporting market demand effectively.
  • Significant growth in the Medicare payer channel, up 130% year-over-year, helped drive recovery in lymphedema sales.
  • Updated full-year revenue guidance raised to $317-$321 million, indicating an 8% to 10% growth outlook.
This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TCMD on AllInvestView.

Get the Full Picture on TCMD

Track Tactile Systems Technology, Inc. in your portfolio with real-time analytics, dividend tracking, and more.

View TCMD Analysis